BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8541096)

  • 1. Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres.
    Longo G; Federico M; Pieresca C; Avanzini P; Iannitto E; Di Prisco AU; Baldini L; Brugiatelli M; Clò V; Bevini M
    Eur J Cancer; 1995 Oct; 31A(11):1763-7. PubMed ID: 8541096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Longo G; Fiorani C; Sacchi S; Callea V; Lombardo M; Federico M; Stelitano C; Angrilli F; Vallisa D; Gobbi PG; Ilariucci F; Frassoldati A; Petrini M; Silingardi V
    Haematologica; 1999 May; 84(5):425-30. PubMed ID: 10329921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.
    Zinzani PL; Bendandi M; Martelli M; Falini B; Sabattini E; Amadori S; Gherlinzoni F; Martelli MF; Mandelli F; Tura S; Pileri SA
    J Clin Oncol; 1996 Mar; 14(3):955-62. PubMed ID: 8622045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
    Baldini L; Guffanti A; Gobbi P; Colombi M; Federico M; Avanzini P; Cavanna L; Pieresca C; Silingardi V; Maiolo AT
    Cancer; 1997 Mar; 79(6):1234-40. PubMed ID: 9070503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood.
    Tomaszewski MM; Moad JC; Lupton GP
    J Am Acad Dermatol; 1999 May; 40(5 Pt 2):857-61. PubMed ID: 10321635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
    Lombardo M; Morabito F; Merli F; Molica S; Cavanna L; Sacchi S; Broglia C; Angrilli F; Ilariucci F; Stelitano C; Luisi D; Bertè R; Luminari S; Federico M; Brugiatelli M;
    Leuk Lymphoma; 2002 Sep; 43(9):1795-801. PubMed ID: 12685834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaplastic large cell (CD30/Ki-1+) lymphoma in HIV+ patients: clinical and pathological findings in a group of ten patients.
    Nosari A; Cantoni S; Oreste P; Schiantarelli C; Landonio G; Alexiadis S; Gargantini L; Caggese L; Gambacorta M; Morra E
    Br J Haematol; 1996 Dec; 95(3):508-12. PubMed ID: 8943892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary gastric CD30 (Ki-1)-positive large cell non-Hodgkin's lymphomas. A clinicopathologic analysis of six cases.
    Paulli M; Rosso R; Kindl S; Boveri E; Bonoldi E; Stracca V; Motta T; Arrigoni G; Lazzarino M; Menestrina F
    Cancer; 1994 Feb; 73(3):541-9. PubMed ID: 8299075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma.
    Nadali G; Vinante F; Stein H; Todeschini G; Tecchio C; Morosato L; Chilosi M; Menestrina F; Kinney MC; Greer JP
    J Clin Oncol; 1995 Jun; 13(6):1355-60. PubMed ID: 7751879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic large cell lymphoma (CD30 +/Ki-1+): results of a prospective clinico-pathological study of 69 cases.
    Pileri S; Bocchia M; Baroni CD; Martelli M; Falini B; Sabattini E; Gherlinzoni F; Amadori S; Poggi S; Mazza P
    Br J Haematol; 1994 Mar; 86(3):513-23. PubMed ID: 7519036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies.
    Reiter A; Schrappe M; Tiemann M; Parwaresch R; Zimmermann M; Yakisan E; Dopfer R; Bucsky P; Mann G; Gadner H
    J Clin Oncol; 1994 May; 12(5):899-908. PubMed ID: 8164040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.
    Verdonck LF; Dekker AW; de Gast GC; van Kempen ML; Lokhorst HM; Nieuwenhuis HK
    J Clin Oncol; 1992 Dec; 10(12):1949-54. PubMed ID: 1453209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of therapy of different variants of anaplastic large T-cell lymphomas].
    Vinogradova IuE; Lutsenko IN; Kaplanskaia IB; Vorob'ev IA; Samoĭlova RS; Gorgidze LA; Ryzhikova NA; Valiev TT; Giliazitdinova EA; Dzhulakian UL; Egorova EK; Zvonkov EE; Krasil'nikova BB; Magomedova AU; Margolin OV; Mar'in DS; Kremenetskaia AM; Kravchenko SK; Vorob'ev AI
    Ter Arkh; 2008; 80(7):33-7. PubMed ID: 18763592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
    Hou M; Li L; Qiu M; Yan X; Zhu J; Gou HF
    Ai Zheng; 2005 Apr; 24(4):461-4. PubMed ID: 15820070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center.
    Park SJ; Kim S; Lee DH; Jeong YP; Bae Y; Han EM; Huh J; Suh C
    Yonsei Med J; 2008 Aug; 49(4):601-9. PubMed ID: 18729302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic large cell lymphoma, ALK-positive.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.